Related Experiment Video
Updated: Oct 29, 2025
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
914
Animal models for diabetes insipidus.
Javier Mahía1, Antonio Bernal1
1Department of Psychobiology, and Mind, Brain and Behavior Research Center, University of Granada, Granada, Spain.
Handbook of Clinical Neurology
|July 9, 2021
Summary
Arginine vasopressin (AVP) regulates water balance. Deficits or resistance to AVP cause diabetes insipidus (DI), leading to excessive urination and thirst. This study examines DI types, animal models, and potential drug treatments.
Area of Science:
- Endocrinology
- Nephrology
- Physiology
Background:
- Arginine vasopressin (AVP) is a key hormone regulating water homeostasis.
- Dysfunction in AVP signaling causes central or nephrogenic diabetes insipidus (CDI/NDI).
- These conditions lead to polyuria, polydipsia, and electrolyte imbalances.
Purpose of the Study:
- To investigate the determinants of water and mineral salt balance in humans and animal models of diabetes insipidus.
- To characterize the hydromineral profiles of various DI models.
- To evaluate the therapeutic potential of AVP analogues, oxytocin, and sildenafil in DI.
Main Methods:
- Review of human DI pathophysiology.
- Characterization of AVP mutant rats and acquired CDI/NDI animal models.
- Analysis of water/salt intake and excretion, and responses to hypertonic NaCl and low-sodium diets.
- Assessment of drug effects (AVP analogues, oxytocin, sildenafil).
Main Results:
- Established determinants of water and salt balance in different DI types.
- Detailed hydromineral characteristics of animal models.
- Demonstrated efficacy of AVP analogues and oxytocin in CDI models.
- Showcased sildenafil's potential to enhance aquaporin-2 in NDI models.
Conclusions:
- Understanding DI pathophysiology is crucial for managing water-electrolyte disturbances.
- Animal models provide valuable insights into DI mechanisms and treatment strategies.
- Pharmacological interventions like AVP analogues, oxytocin, and sildenafil show promise for treating CDI and NDI.
